Insider Trading November 18, 2026 09:45 PM

AIM ImmunoTech CEO Thomas Equels Adds 20,000 Shares in Small Open-Market Purchase

The buy, valued at $2,680, comes as the stock trades near its 52-week low and sits roughly 90% lower over the past year.

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
AIM

AIM ImmunoTech CEO and President Thomas K. Equels acquired 20,000 shares of the company's common stock at $0.134 per share, a transaction valued at $2,680 and reported on November 18, 2026. The purchase lifts his direct ownership to 386,095 shares. The insider buy arrives with the stock near its 52-week low of $0.12 and down approximately 90% over the past year. According to InvestingPro analysis, the shares appear undervalued at current levels and trade below the platform's Fair Value estimate. The company maintains more cash than debt on its balance sheet, though InvestingPro Tips highlight ongoing profitability challenges. The article does not provide additional context on the executive's rationale or the company's operating results.

AIM ImmunoTech CEO Thomas Equels Adds 20,000 Shares in Small Open-Market Purchase
AIM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO and President Thomas K. Equels bought 20,000 AIM ImmunoTech shares at $0.134 each, a $2,680 transaction reported on November 18, 2026, lifting his direct holdings to 386,095 shares.
  • The purchase occurred as the stock traded near its 52-week low of $0.12 and roughly 90% below its level from a year earlier, according to the report.
  • InvestingPro analysis cited in the disclosure indicates the stock appears undervalued and trades below the platform's Fair Value estimate, while the company holds more cash than debt but faces ongoing profitability challenges.

AIM ImmunoTech Inc. (NASDAQ:AIM) disclosed that its chief executive and president, Thomas K. Equels, acquired 20,000 shares of the company's common stock in a transaction reported on November 18, 2026. The shares were purchased at $0.134 apiece, putting the total value of the buy at $2,680.

Equels, who also serves as a director of the company, now directly owns 386,095 shares of AIM ImmunoTech common stock following the acquisition, according to the disclosure.

The open-market purchase lands at a moment when the stock is trading near its 52-week low of $0.12. Shares have fallen approximately 90% over the past year, a decline that frames the insider transaction against a backdrop of sustained weakness in the equity.

According to InvestingPro analysis, the stock appears undervalued at current levels, with shares changing hands below the platform's Fair Value estimate. The same analysis notes that the company maintains more cash than debt on its balance sheet, a balance-sheet characteristic that stands apart from the stock's market performance. At the same time, InvestingPro Tips highlight ongoing profitability challenges for the company.

The disclosure does not include a stated reason for the purchase, and no additional details about the executive's plans, the company's operations, or its financial outlook were provided in the report. Investors seeking a fuller picture can access 13 additional ProTips and comprehensive financial metrics on the InvestingPro platform.

For readers tracking insider activity, the key figures in this filing are straightforward: 20,000 shares acquired, a $0.134 purchase price, a $2,680 total transaction value, and a resulting direct holdings position of 386,095 shares. The stock's proximity to its 52-week low of $0.12 and its roughly 90% decline over the past year provide the market context against which the purchase was reported.

The article does not offer guidance on whether the transaction signals a change in the company's prospects, nor does it include commentary from the executive or the company. It also does not specify the exact date the shares were acquired, beyond the November 18, 2026 reporting date.

What the report does make clear is the scale of the purchase relative to the stock's recent trading range and the executive's resulting stake. The buy is small in dollar terms, but it is an open-market acquisition by the company's top executive and a board member, reported at a time when the shares are near the bottom of their 52-week range.

The disclosure also leaves several questions unanswered: whether further purchases are planned, how the transaction fits into any broader insider buying pattern, and what specific factors informed the decision to buy at this price. Those details are not included in the report, and this article does not speculate beyond the disclosed facts.

For now, the disclosed transaction stands on its own terms: a 20,000-share purchase at $0.134 per share, a total outlay of $2,680, and direct ownership of 386,095 shares, reported as the stock trades near its 52-week low and well below where it stood a year ago.

Risks

  • The stock's steep decline, down approximately 90% over the past year and near its 52-week low, reflects sustained market weakness that could persist despite the insider purchase.
  • InvestingPro Tips cited in the report flag ongoing profitability challenges, a risk that may weigh on the equity independent of balance-sheet cash levels.
  • The disclosure provides no stated rationale for the purchase and no forward-looking commentary, leaving investors without context on whether additional insider buying or operational changes may follow.

More from Insider Trading

Jack Henry Accounting Chief Swearingen Sells $159,695 in Stock, Gifts Shares Nov 18, 2026 Revolution Medicines Insider Sale: Stephen Kelsey Offloads $4.5 Million in Stock Nov 18, 2026 PubMatic Accounting Chief Gimbel Offloads $27,887 in Shares to Cover RSU Tax Bill Nov 18, 2026 Constellation Brands 10% Holder AJB Business Holdings Offloads 75,000 Shares for $10.88 Million Nov 18, 2026 Figma Director Radakovich Offloads $395K in Stock Near 52-Week Low Nov 18, 2026